Indivior PLC (INDV) Announces Full-Year 2026 Financial Guidance
Indivior PLC (NASDAQ:INDV) is one of the best performing pharma stocks in 2025.
Indivior Pharmaceuticals Inc. (INDV)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Seas Capital Sina Toussi | 10,504,152 | $253,255,105 | -8% | 4.07% |
| 2. | Deerfield Management James E. Flynn | 6,986,811 | $168,452,013 | -34% | 2.57% |
| 3. | Madison Avenue Partners Eli Samaha | 6,463,585 | $155,837,034 | -19% | 9.3% |
| 4. | Newtyn Management Noah Levy And Eugene Dozortsev | 4,200,000 | $101,262,000 | +62% | 12.4% |
| 5. | Divisadero Street Capital William Zolezzi | 3,362,605 | $81,072,407 | +2373% | 3.54% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $35.39 | 775 | $27,429.27 | 1,963 | 2026-01-05 | Filing | |
| $35.39 | 775 | $27,429.27 | 5,802 | 2026-01-05 | Filing | |
| $35.39 | 775 | $27,429.27 | 16,923 | 2026-01-05 | Filing | |
| $35.39 | 775 | $27,429.27 | 16,847 | 2026-01-05 | Filing | |
| $35.39 | 1,771 | $62,680.29 | 14,395 | 2026-01-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,473,891 | $196,403,209 | 0% | |
| 2. | 788,566 | $28,293,748 | 0% | |
| 3. | 317,600 | $11,395,488 | 0.39% | |
| 4. | 116,261 | $4,171,445 | 0.08% | |
| 5. | 83,135 | $2,982,884 | 0% |
News See All
10 Best Performing Pharma Stocks in 2025
On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his bullish outlook on biopharma stocks in 2026 and the pharma M&A outlook...
Indivior PLC (NASDAQ:INDV) Q3 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Indivior PLC Q3 Results 2025 Webcast and Conference Call.
Indivior (INDV) Jumps to New High on Earnings Blowout, Optimistic Outlook
Indivior climbed for a third straight day on Thursday to reach a new all-time high, as investors cheered a stellar earnings performance and a highly optimistic business outlook for the rest of the year...
Indivior PLC (INDV) Raises 2025 Guidance After Q2 Revenue Hits $302M
Indivior PLC (NASDAQ:INDV) is a pharmaceutical company specializing in treatments for opioid use disorder (OUD), with its core products SUBLOCADE, a once-monthly buprenorphine injection, and SUBOXONE ...
12 Best Performing Healthcare Stocks to Buy Right Now
Spending on healthcare in the US is predicted to hit $5.3 trillion this year, making it one of the largest in the world.
Indivior Plc (INDV) Jumps 22.8% on Impressive Earnings, Outlook
In an updated report last week, Indivior PLC (NASDAQ:INDV) said that it swung to a net income of $18 million in the second quarter of the year from a $97 million net loss in the same period last year...
Indivior PLC (NASDAQ:INDV) Q2 2025 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Indivior Second Quarter 2025 Results Conference Call and Webcast.
Indivior (INDV) Extends Jump on 3rd Day with 16% Gain
Indivior PLC (NASDAQ:INDV) announced in its updated report that it swung to a net income of $18 million in the second quarter of the year from a $97 million net loss in the same period last year.
Indivior PLC (INDV) Reinvents Leadership, Moves Listing to Nasdaq
Indivior PLC (NASDAQ:INDV) is a pharmaceutical company focused on opioid addiction treatment, particularly through its flagship product SUBLOCADE, a monthly buprenorphine injection.
Hedge Fund Resource Center Billionaire Hedge Funds
